Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Loc

Determine the Clinical Benefit Rate (CBR) at 24 weeks amongst patients receiving triple therapy with ribociclib + everolimus + exemestane, for advanced/metastatic HR+, HER2-negative breast cancer following progression on CDK 4/6 inhibitor.

November 16, 2016